Although the World Health Organization has approved the new, experimental Ebola medication ZMapp, the limited supply of the drug raises questions about which patients should be prioritized for treatment.
ABC News said, "ZMapp...has notably not been supplied to the Africans who make up the majority of victims."
Bioethics director Robert Klitzman commented, "We want to make sure that we have clear criteria to make sure that it's done fairly."
